Eli Lilly, the American pharmaceutical company challenging Ozempic manufacturer Novo Nordisk, shows impressive growth in its latest quarterly report.
The revenue for the quarter amounted to 12.7 billion dollars, equivalent to 123 billion kronor. An increase of 45 percent compared to the same period last year.
The stock fell by over four percent in trading in New York despite this. The reason is the company's forecast for the full year 2025, where they have scaled down the expected profit per share by a couple of dollars following a major acquisition of a cancer treatment.
Eli Lilly manufactures the diabetes medicine Mounjaro and the weight loss injection Zepbound. Moreover, they have carried out successful trials with a weight loss pill, orfoglipron, which has given Novo Nordisk some tough stock market setbacks.
